Italy is faced with an unprecedented situation: the COVID-19 health emergency has changed our lives, putting us to the test. In the face of this challenge, we have joined forces and made our skills available to respond hand in hand with the rest of the country.
During a global emergency such as this, we must mobilize all available resources to overcome the challenges ahead. We are proud to contribute to finding solutions to this challenge facing humanity.
We provided immediate support to frontline workers managing the COVID-19 health emergency, drawing upon wide-ranging experience gained from health care projects around the world, implementing numerous medical and health care projects and launching major initiatives to support local health authorities in the regions where we operate.
Among our many commitments, we are the sole partner of Agostino Gemelli University Policlinic in building its COVID 2 Hospital in Rome (formerly the private Columbus Hospital), exclusively dedicated to the care of patients suffering from coronavirus. The financial commitment to these projects amounts to approximately 35 million euros. And to tackle the fight against the COVID-19 pandemic, we have made the HPC5 supercomputer, the world's most powerful industrial supercomputer, available for research. In the field of communication, we have financed public information campaigns with the Italian Federation of general practitioners on the role of the family doctor as the primary point of contact in the fight against COVID-19, as well as a campaign on informing the elderly about services they can access for assistance in their daily needs, as they have not been able to leave their home for an extended period. In addition, we have also made our company fleets available, supporting those who are at the forefront of health emergencies every day. Then, in the Versalis plant in Crescentino (near Vercelli), we have started production of a new line of hand disinfectant, whose active ingredient is ethanol, obtained from raw vegetable material, to support growing demand in Italy for this personal protective equipment. It has already been distributed and donated to ARPA Piedmont and Piedmont’s civil protection department.
We have made our HPC5 supercomputing infrastructure and molecular modelling skills freely available for coronavirus research, offering the highest quality tools and resources to the fight against this global emergency.
This collaboration is part of the European Exscalete4Cov initiative, which is bringing together leading institutions and research centres from Italy and across Europe to identify the safest and most promising drugs to tackle coronavirus. We are contributing to the project in partnership with Cineca, a non-profit research consortium that includes universities, national research centres and the Italian Ministry of Education, University and Research.
Our joint team will carry out dynamic molecular simulations of the proteins present on the surface of the SARS-CoV-2 virus. These proteins play a key role in the virus’s infection mechanism. This work was essential in order to proceed to the next phase of the Dompé-driven project, namely the screening of 10,000 active ingredients of the pharmaceutical compounds known today, in order to identify those most effective at blocking the virus. This was followed by the Fast Track phase, carried out in mid-November 2020, during which the supercomputer was used in the molecular dynamic simulation of viral proteins considered relevant to the mechanism of infection of Covid-19. The screening was aimed at selecting the molecules with the highest anti-viral efficacy. Interactions between virus proteins and over 71.6 billion molecules have been reproduced on the computer using sophisticated molecular dynamics calculations to identify structures capable of attacking the virus with the aim of identifying those with the most effective pharmacological activity. If this research is successful, we will obtain a drug that has already undergone clinical testing, thus making it immediately available.
This website uses cookies to show you adverts and offer you services customised according to the preferences you have shown while browsing online. For further information please refer to our cookie policy.
THIS WEBSITE (AND THE INFORMATION CONTAINED HEREIN) DOES NOT CONTAIN OR CONSTITUTE AN OFFER OF SECURITIES FOR SALE, OR SOLICITATION OF AN OFFER TO PURCHASE SECURITIES OR IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR FOR THE ACCOUNT OR BENEFIT OF ANY U.S. PERSON AS THAT TERM IS DEFINED IN THE SECURITIES ACT (A "U.S. PERSON"), AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH AN OFFER OR SOLICITATION WOULD REQUIRE THE APPROVAL OF LOCAL AUTHORITIES OR OTHERWISE BE UNLAWFUL (THE "OTHER COUNTRIES"). THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR PURSUANT TO THE CORRESPONDING REGULATIONS IN FORCE IN AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR THE “OTHER COUNTRIES” AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO A U.S. PERSON UNLESS THE SECURITIES ARE REGISTERED UNDER THE SECURITIES ACT, OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT IS AVAILABLE. NO PUBLIC OFFERING OF SUCH SECURITIES IS INTENDED TO BE MADE IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR IN THE “OTHER COUNTRIES.”
In any Member State of the European Economic Area ("EEA"), the information contained in this website is only directed at and may only be communicated to persons who are "qualified investors" ("Qualified Investors") within the meaning of Article 2(e) of Regulation (EU) 2017/1129 (the "Prospectus Regulation").
The information to which this website gives access is directed only at persons (i) who are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (ii) who have professional experience in matters relating to investments falling within Article 19(5) of the Order or (iii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this communication relates is only available to relevant persons and will be engaged in only with relevant persons, or in the EEA, with Qualified Investors. Any person who is not a relevant person, a Qualified Investor or otherwise permitted under applicable law or regulation to access the information, should not act or rely on the information contained herein.
Confirmation of Understanding and Acceptance of Disclaimer
These materials are for informational purposes only and are not directed to, nor are they intended for, access by persons located or resident in the United States, Australia, Canada, Japan or South Africa or any of the Other Countries. I certify that:
I am not resident of, or located in, the United States, Australia, Canada, Japan or South Africa or any of the Other Countries or I am not a U.S. Person; or
If I am a resident of, or located in, the EEA, I am a Qualified Investor within the meaning of Article 2(e) of the Prospectus Regulation; or
If I am a resident of, or located in, the United Kingdom, I am a Qualified Investor and a relevant person.
I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms and I am permitted under applicable law and regulations to proceed to the following parts of this website.
WARNING: the above certification constitutes a "self-certification" pursuant to Decree of the President of the Italian Republic No. 445 of 28 December 2000. False certifications are punishable by law.
